HIV-1 viral protein R (Vpr) induction of apoptosis and cell cycle arrest in multidrug-resistant colorectal cancer cells

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 358-364

  Ma, Bo ^a   Zhang, Hanchao ^a,b   Wang, Jinhuan ^c   Zhang, Biao ^c   Xu, Xinnv ^a   Cheng, Binglu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c TIANJIN HUANHU HOSPITAL   (China)

Author keywords

Apoptosis; Chemoresistance; Colorectal cancer; G2 M arrest; HIV1 Vpr

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN B1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; SYNAPTOTAGMIN I; VPR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; GENE ACTIVITY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION;

ADENOVIRIDAE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; NF-KAPPA B; RECOMBINANT PROTEINS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84861560240     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1782     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Herszenyi L and Tulassay Z: Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 14: 249-258, 2010.
3. O'Neil BH and Goldberg RM: Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can). Semin Oncol 32: 35-42, 2005. (Pubitemid 40250124)
4. Venook A: Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10: 250-261, 2005.
5. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
6. Zhang Y, Yuan J, Zhang HY, et al: Natural resistance to apoptosis correlates with resistance to chemotherapy in colorectal cancer cells. Clin Exp Med: June 19, 2011 (Epub ahead of print).
7. Muthumani K, Zhang D, Hwang DS, et al: Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene 21: 4613-4625, 2002. (Pubitemid 34833139)
8. Muthumani K, Choo AY, Hwang DS, Ugen KE and Weiner DB: HIV-1 Vpr: enhancing sensitivity of tumors to apoptosis. Curr Drug Deliv 1: 335-344, 2004.
9. Muthumani K, Choo AY, Premkumar A, et al: Human immunodeficiency virus type 1 (HIV-1) Vpr-regulated cell death: insights into mechanism. Cell Death Differ 12 (Suppl 1): 962-970, 2005. (Pubitemid 41030609)
10. Muthumani K, Lambert VM, Shanmugam M, et al: Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther 8: 180-187, 2009.
11. Nonaka M, Hashimoto Y, Takeshima SN and Aida Y: The human immunodeficiency virus type 1 Vpr protein and its carboxy-terminally truncated form induce apoptosis in tumor cells. Cancer Cell Int 9: 20, 2009.
12. Nyland SB and Loughran TP: Putting HIV-1 apoptosis mediators to work against cancer: a killer job, with benefits. Cancer Biol Ther 8: 188-191, 2009.
13. Muthumani K, Lambert VM, Sardesai NY, et al: Analysis of the potential for HIV-1 Vpr as an anti-cancer agent. Curr HIV Res 7: 144-152, 2009.
14. Muthumani K, Lambert VM, Kawalekar O, et al: Anti-cancer activity of the HIV accessory molecule viral protein R (Vpr): Delivery as a DNA expression plasmid or biologically active peptides. Vaccine 28: 2005-2010, 2010.
15. Zhao RY, Liang D, Li G, Larrimore CW and Mirkin BL: Anti-cancer effect of HIV-1 viral protein R on doxorubicin resistant neuroblastoma. PLoS One 5: e11466, 2010.
16. Sherman MP, Schubert U, Williams SA, et al: HIV-1 Vpr displays natural protein-transducing properties: Implications for viral pathogenesis. Virology 302: 95-105, 2002. (Pubitemid 35356858)
17. Muthumani K, Hwang DS, Desai BM et al: HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 277: 37820-37831, 2002.
18. Varin A, Decrion AZ, Sabbah E, et al: Synthetic Vpr protein activates activator protein-1, c-Jun N-terminal kinase, and NF-kappaB and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. J Biol Chem 280: 42557-42567, 2005. (Pubitemid 43049213)
19. Zhang B, Feng X, Wang J, Xu X, Lin N and Liu H: Combined antitumor effect of Ad-bFGF-siRNA and Ad-Vpr on the growth of xenograft glioma in nude mouse model. Pathol Oncol Res 17: 237-242, 2011.
20. Han Y, Bu LM, Ji X, Liu CY and Wang ZH: Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line. Chin J Dig Dis 6: 82-86, 2005. (Pubitemid 40936490)
21. Brunelle JK and Letai A: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122: 437-441, 2009.
22. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002. (Pubitemid 37328783)
23. Luo JL, Kamata H and Karin M: IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 115: 2625-2632, 2005. (Pubitemid 41434385)
24. Karin M: NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45: 355-361, 2006.
25. Pacifico F and Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol 72: 1142-1152, 2006.
26. Lind DS, Hochwald SN, Malaty J, et al: Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 130: 363-369, 2001. (Pubitemid 32721692)
27. Yu YY, Li Q and Zhu ZG: NF-kappaB as a molecular target in adjuvant therapy of gastrointestinal carcinomas. Eur J Surg Oncol 31: 386-392, 2005. (Pubitemid 40521305)
28. Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62, 2007.
29. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.
30. Aggarwal BB: Nuclear factor-kappa-B: The enemy within. Cancer Cell 6: 203-208, 2004.
31. Danial NN and Korsmeyer SJ: Cell death: critical control points. Cell 116: 205-219, 2004. (Pubitemid 38167313)
32. Jacotot E, Ferri KF, El Hamel C, et al: Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 193: 509-519, 2001. (Pubitemid 32524481)
33. Muthumani K, Hwang DS, Desai BM, et al: HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 277: 37820-37831, 2002.
34. He F, Zeng Y, Wu X, et al: Endogenous HIV-1 Vpr-mediated apoptosis and proteome alteration of human T-cell leukemia virus-1 transformed C8166 cells. Apoptosis 14: 1212-1226, 2009.
35. Snyder A, Alsauskas ZC, Leventhal JS, et al: HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. AIDS 24: 1107-1119, 2010.
36. Snyder A and Ross MJ: Murine models of Vpr-mediated pathogenesis. Curr HIV Res 7: 129-135, 2009.
37. Ayyavoo V, Mahboubi A, Mahalingam S, et al: HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med 3: 1117-1123, 1997. (Pubitemid 27444453)
38. Muthumani K, Desai BM, Hwang DS, et al: HIV-1 Vpr and anti-inflammatory activity. DNA Cell Biol 23: 239-247, 2004. (Pubitemid 38591235)
39. Roux P, Alfieri C, Hrimech M, Cohen EA and Tanner JE: Activation of transcription factors NF-kappaB and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expression. J Virol 74: 4658-4665, 2000. (Pubitemid 30237891)
40. Cude K, Wang Y, Choi HJ, et al: Regulation of the G2-M cell cycle progression by the ERK5-NF kappa B signaling pathway. J Cell Biol 177: 253-264, 2007. (Pubitemid 46658637)
41. Li G, Elder RT, Qin K, Park HU, Liang D and Zhao RY: Phosphatase type 2A-dependent and -independent pathways for ATR phosphorylation of Chk1. J Biol Chem 282: 7287-7298, 2007. (Pubitemid 47093684)
42. Barisic S, Strozyk E, Peters N, Walczak H and Kulms D: Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Differ 15: 1681-1690, 2008.